Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia
Authors:
- 1 November 1991
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 27 (6) , 456-463
Abstract
Since 1978, over 50 clinically useful antitumor drugs or new candidate antitumor agents have been evaluated in vivo against cisplatin-resistant P388 leukemia (P388/DDPt) in our laboratories. Analysis of this data base has yielded insights into the cross-resistance, collateral sensitivity, and mechanisms of resistance of P388/DDPt. P388/DDPt was cross-resistant or marginally crossresistant to eight agents [carmethizole·HCl, rhizoxin, dibromodulcitol, spirohydantoin mustard, hepsulfam, arabinosyl-5-azacytosine (ara-AC), tiazofurin, and deoxyspergualin]. Of these eight agents, the latter six have entered various phases of clinical trials. For these trials, it may be important to exclude or to monitor with extra care patients who have previously been treated with cisplatin. P388/DDPt was collaterally sensitive to six agents [fludarabine phosphate (2-F-ara-AMP), amsacrine (AMSA), mitoxantrone, etoposide (VP-16), batracylin, and flavone acetic acid] and, possibly, to two others (merbarone and echinomycin). These observations of collateral sensitivity suggest that a combination of cisplatin plus any one of these drugs might exhibit therapeutic synergism. Therapeutic synergism has been observed in animal models for combinations of cisplatin plus VP-16, AMSA, or mitoxantrone. The observation of collateral sensitivity for P388/DDPt to four agents (AMSA, mitoxantrone, merbarone, and VP-16) that have been reported to interact with DNA topoisomerase II suggests the possible involvement of the latter in cisplatin resistance. Both the increased sensitivity of P388/DDPt to these agents and a portion of its resistance to cisplatin could be the result of an increase in DNA topoisomerase II activity.Keywords
This publication has 26 references indexed in Scilit:
- Tumor Resistance to Alkylating Agents Conferred by Mechanisms Operative Only in VivoScience, 1990
- Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumoursCancer Chemotherapy and Pharmacology, 1989
- Preclinical antitumor activity of batracylin (NSC 320846)Investigational New Drugs, 1988
- Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell lineCancer Letters, 1988
- Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivoInvestigational New Drugs, 1987
- Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trialsInvestigational New Drugs, 1987
- Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells.Proceedings of the National Academy of Sciences, 1987
- Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.Proceedings of the National Academy of Sciences, 1984
- ROLE OF TOPOISOMERASE-II IN MEDIATING EPIPODOPHYLLOTOXIN-INDUCED DNA CLEAVAGE1984
- Echinomycin: a bifunctional intercalating antibioticNature, 1974